United Therapeutics Corp. Dec. 9 disclosed that it has received a subpoena from the Department of Health and Human Services Office of Inspector General seeking information about promotional practices related to three of its drug products.
The company said the subpoena requested documents regarding the pulmonary arterial hypertension (PAH) treatments Remodulin (treprostinil) Injection and Tyvaso (treprostinil) Inhalation Solution and Adcirca (tadalafil) Tablets. Adcirca is used to increase exercise ability for people with pulmonary arterial hypertension.
The subpoena relates to an investigation by the Department of Justice, principally represented by the U.S. Attorney’s Office for the District of Maryland, Baltimore.
The ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.